Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors.

Rheumatology (Oxford) · 2025 · PMC12596071 · PMID 40632603

Europe PMC DOI

hedged sentence

0.0579

closest p · 1.2× alpha

0.0579

boldest claim

The sentences

showed a trendP = 0.0579so close (0.05 < p ≤ 0.1)

RA patients showed a trend towards decreased CD126 + lymphocytes (mean [ s . d .] 52 [11]%; median 55 [27–81]%; Mann–Whitney P = 0.0579) compared with healthy individuals, but higher ( P = 0.0149) than SLE patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.